Sanofi has bought back a 鈧�3bn ($3.1bn) stake held by cosmetics giant L’Or茅al, the first of multiple share buybacks the French drugmaker has planned for 2025.
L’Or茅al was selling 29,556,650 shares at 鈧�101.50 each, meaning its stake in Sanofi will decrease from 9.4% to 7.2%. Both listed in Paris, L’Or茅al opened 2.5% lower on 3 February following the announcement whilst Sanofi opened 0.4% down.
The cosmetics company has held shares in Sanofi since 1999 and received $431m in dividends from the drugmaker in 2022 alone.
The transaction of shares represents a 2.8% discount on where Sanofi鈥檚 shares closed on 31 January. The pharma company鈥檚 shares have been flying high after raising its full-year profit outlook propelled by blockbuster asthma drug Dupixent (dupilumab) and new launches such as respiratory syncytial virus (RSV) vaccine Beyfortus (nirsevimab), developed as part of a partnership with AstraZeneca.
Whilst revealing its Q4 2024 results, Sanofi said it is planning to execute a $5.12bn share buyback programme in 2025. As of June 2024, Sanofi鈥檚 stakeholder structure comprised 67% owned by non-French institutional investors and 10.8% owned by French institutions. Individual shareholders and employees amounted to 5.3% and 2.6% of the drugmaker respectively. At the time, L’Or茅al held 9.4%, with the remaining shares either unassigned or held via 鈥榤iscellaneous鈥� buyers.
Sanofi鈥檚 chief financial officer Fran莽ois Roger said: 鈥淭his transaction highlights Sanofi’s dedication to sustainable value creation while upholding our strategic priorities and preserving the strength of our key partnerships.鈥�
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSanofi is in the process of transitioning into a pure vaccine and drug manufacturer as the company edges closer to closing a deal that would see it sell a controlling stake in its consumer health company Opella. In October 2024, Sanofi entered talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of Opella, valued at around $17bn. A deal is slated to be completed by Q2 this year.
The share buyback comes nearly a week after Robert F Kennedy Jr was questioned on his anti-vaccine stance by senators ahead of potentially heading up the US Health and Human Services (HHS). Sanofi was one of many vaccine manufacturers whose shares took a temporary hit when he was announced as the nominee for the position by President Donald Trump late last year.
Sanofi is not the only big pharma company targeting a share buyback campaign. On the back of booming popularity for diabetes and weight loss treatments, Eli Lilly plans to buy back around $15bn in shares, as announced in December 2024. Buying back stock is a way for companies with auxiliary cash to boost earnings per share. It also increases the value of remaining shares and adjusts voting rights.
